Skip to main content

Advertisement

SpringerLink
Log in

Update on systemic therapy for clear cell renal cell carcinoma

  • short review
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Summary

The treatment landscape of advanced and metastatic renal cell carcinoma (RCC) has changed fundamentally over the last two decades with the introduction of tyrosine kinase inhibitors (TKIs) in 2005 and immune checkpoint inhibitors (ICIs) about 10 years later, both demonstrating significantly improved overall survival (OS) rates across all RCC risk categories. Currently, combination therapies represent the standard-of-care in the first-line setting of clear cell RCC in almost all cases. In this short review article, the most recent therapeutic advances in early and advanced stage of clear cell RCC are summarized.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Choueiri TK, Tomczak P, Park SH, et al. Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. N Engl J Med. 2021;385:683–94.

    Article  CAS  PubMed  Google Scholar 

  2. Choueiri TK, Tomczak P, Park SH, et al. Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma: Results from 30-month follow-up of KEYNOTE-564. J Clin Oncol. 2022;40(6_suppl):290.

    Article  Google Scholar 

  3. Motzer RJ, Russo P, Guenwald V, et al. Adjuvant nivolumab plus ipilimumab (NIVO+IPI) vs placebo (PBO) for localized renal cell carcinoma (RCC) at high risk of relapse after nephrectomy: Results from the randomized, phase III CheckMate 914 trial. Ann Oncol. 2022;33(7_suppl):S808–S69.

    Google Scholar 

  4. Bex A, Uzzo R, Karam JA, Master VA, et al. IMmotion010: Efficacy and safety from the phase III study of atezolizumab (atezo) vs placebo (pbo) as adjuvant therapy in patients with renal cell carcinoma (RCC) at increased risk of recurrence after resection. Ann Oncol. 2022;33(7_suppl):S808–S69.

    Google Scholar 

  5. Allaf M, Kim SE, Harshman LC, McDermott DF, et al. Phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients (Pts) with renal cell carcinoma (RCC) undergoing nephrectomy (PROSPER, ECOG-ACRIN EA8143), a National Clinical Trials Network trial. Ann Oncol. 2022;33(7_suppl):S808–S69.

    Google Scholar 

  6. Powels T, Albiges L, Bex A, et al. ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma. Ann Oncol. 2021;32(12):1511–9.

    Article  Google Scholar 

  7. Motzer RJ, Tannir NM, McDermott DF, et al. Conditional survival and 5‑year follow-up in CheckMate 214: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in advanced renal cell carcinoma (aRCC). Ann Oncol. 2021;32(suppl_5):S678.

    Google Scholar 

  8. Tannir NM, Signoretti S, Choueiri TK, et al. Efficacy and safety of nivolumab plus ipilimumab (N+I) versus sunitinib (S) for first-line treatment of patients with advanced sarcomatoid renal cell carcinoma (sRCC) in the phase 3 CheckMate 214 trial with extended 5‑year minimum follow-up. J Clin Oncol. 2022;40(6_suppl):352.

    Article  Google Scholar 

  9. Rini BL, Plimack ER, Stus V, et al. Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426. J Clin Oncol. 2021;39(15_suppl):4500.

    Article  Google Scholar 

  10. Powels T, Choueiri TK, Burotto M, Escudier B, et al. Final overall survival analysis and organ-specific target lesion assessments with two-year follow-up in CheckMate 9ER: Nivolumab plus cabozantinib versus sunitinib for patients with advanced renal cell carcinoma. J Clin Oncol. 2022;40(6_suppl):350.

    Article  Google Scholar 

  11. Motzer R, Alekseev B, Rha SY, Porta C, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med. 2021;384(14):1289–300.

    Article  CAS  PubMed  Google Scholar 

  12. Choueiri TK, Powels TB, Albiges L, Burotto M, et al. Phase III study of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC) of IMDC intermediate or poor risk (COSMIC-313). Ann Oncol. 2022;33(7_suppl):S808–S69.

    Google Scholar 

  13. Recio-Boiles A, et al. Network meta-analysis (NMA) of second-line (2L) treatment options in metastatic renal cell carcinoma. J Clin Oncol. 2022;40(6_suppl):337.

    Article  Google Scholar 

  14. Motzer RJ, Hutson TE, Glen H, Michaelson MD, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 2015;16(15):1473–82.

    Article  CAS  PubMed  Google Scholar 

  15. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med. 2005;353(23):2477–90.

    Article  CAS  PubMed  Google Scholar 

  16. Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, et al. Belzutifan for renal cell carcinoma in von Hippel-Lindau disease. N Engl J Med. 2021;385(22):2036–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Bauer TM, Chouieri TK, Papadopoulos KP, et al. The oral HIF‑2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma: updated follow-up of a phase I/II study. J Clin Oncol. 2021;39(6_suppl):273.

    Article  Google Scholar 

  18. Choueiri TK, Albiges L, Fan L, Perini RF, et al. Phase III study of the hypoxia-inducible factor 2α (HIF-2α) inhibitor MK-6482 versus everolimus in previously treated patients with advanced clear cell renal cell carcinoma (ccRCC). J Clin Oncol. 2020;38(15_suppl):TPS5094.

    Article  Google Scholar 

  19. Calvo E, Boni V, Chaudhry A, Debruyne PR, et al. Nemvaleukin alfa in patients with advanced renal cell carcinoma: ARTISTRY‑1. J Clin Oncol. 2022;40(6_suppl):330.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Hospital of Barmherzige Brüder (Brothers of Mercy), Kajetanerplatz 1, 5020, Salzburg, Austria

    Josef Mühlmann

Authors
  1. Josef Mühlmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Josef Mühlmann.

Ethics declarations

Conflict of interest

J. Mühlmann declares that he has no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Published first in JATROS Hämatologie & Onkologie, Ausgabe 5/22.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mühlmann, J. Update on systemic therapy for clear cell renal cell carcinoma. memo 16, 38–41 (2023). https://doi.org/10.1007/s12254-022-00867-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-022-00867-w

Keywords

Search

Navigation